CRMD — CorMedix Inc. · 2026-09-04 · Verdict: WATCH · Conviction 3
Price $8.47 · Mkt cap $665M · EV $558M · EV/LTM EBIT 2.6x · LTM FCF yield 38% · Net cash $107M ($256.7M cash less $150M converts) · ADV ~$11.8M Sources read: 10-K 2026-03-05 (Items 1, 1A, 7, 9A), 10-Q 2026-08-13 (Item 2, Notes 2, 7, 10), DEF 14A 2026-04-29, 8-Ks 2026-03-05, 03-06, 04-27, 05-14, 07-01, 08-13, Form 4s (12m). No transcript was filed; the Q2 release substitutes.
1. What the business actually does
DefenCath (taurolidine and heparin) is the first and only FDA-approved antimicrobial catheter lock solution, approved November 2023 to cut catheter-related bloodstream infections in adults on chronic hemodialysis through a central venous catheter (10-K 2025, Item 1). It was $258.8M of 2025's $311.7M revenue (Item 7), sold to customers covering roughly 60% of US outpatient dialysis centers, with all top five operators now contracted (8-K 2026-08-13). The second leg is Melinta, bought August 2025 for $260M cash plus 3.3M shares: six hospital anti-infectives plus Toprol-XL, about $132M annualized.
2. Why it is mispriced — the edge case
A dateable, mechanical reimbursement reset that makes every trailing screen metric false. DefenCath left TDAPA on July 1, 2026 for a post-TDAPA add-on of $2.37, which the company says will significantly cut its net price (10-K 2025, Item 7; 10-Q Q2 2026, Item 2). The 2.6x trailing EV/EBIT and 38% cash flow yield describe a period that has ended. But I have no edge on what decides the outcome: the 2027 add-on is set by CMS and is not yet published. Management estimates three to five times the H2 2026 rate if the methodology holds, with no assurance it improves (Item 1). That caps the verdict at WATCH.
3. Unit economics and growth
H1 2026 revenue was $229.4M with $128.7M adjusted EBITDA (Q2 alone $101.9M and $58.7M), against FY26 guidance of $325M to $345M revenue and $125M to $140M adjusted EBITDA (8-K 2026-08-13). That implies H2 revenue of $96M to $116M and H2 adjusted EBITDA of negative $3.7M to positive $11.3M. With Melinta at its Q2 run rate ($72M for the half), implied H2 DefenCath revenue is $24M to $44M against $163.6M in H1 (10-Q, Item 2), a 73% to 85% collapse that takes adjusted EBITDA to about zero.
The recovery is smaller than the "three to five times" headline implies: reaffirmed FY2027 DefenCath guidance is $100M to $140M (8-K 2026-03-06), below the roughly $198M of 2026 and far below 2025. That is a lower permanent plateau, on management's own numbers.
Concentration is extreme and uncommitted. Top three customers were 79% of 2025 revenue (10-K, Item 1A); in Q2 2026 four were 27%, 25%, 20% and 10% of revenue, one was 47% of gross receivables, and each DefenCath API has a single approved source (10-Q, Note 2). Competition is not the near-term issue, with exclusivity to November 2033 and patents to 2042 (Item 1). Provider economics after the add-on shrinks is.
4. Balance sheet and capital allocation
$256.7M cash at June 30, 2026 against $150M of 4.00% converts due August 2030 (conversion price $13.47, unmet), so about $107M net cash (10-Q, Notes 7, 10). H1 operating cash flow was $128.6M; with H2 adjusted EBITDA near zero the company stops generating cash rather than burning it. A $75M buyback runs to end-2027, with 2.4M shares retired for $17.5M in H1 (Note 10), yet shares still rose from 74.6M to 78.4M year over year. Insiders and directors own 3.5% (DEF 14A 2026), and Form 4s show zero open-market purchases and zero sales in twelve months, only grants and tax withholding: nobody has bought this drawdown. Two governance flags: a material weakness in control over non-routine transactions at December 31, 2025, and a second auditor change in fifteen months (10-K, Item 9A; 8-K 2026-07-01).
5. Management: what they said vs what they did
Guidance was raised twice into the cliff, from $300M to $320M revenue and $100M to $125M adjusted EBITDA up to $325M to $345M and $125M to $140M (8-Ks 2026-03-05, 05-14, 08-13), and H1 beat their own bar. But holding the revenue range after a $229M first half is itself the disclosure of a very steep second half, which the release never quantifies. Pipeline claims have held: ReSPECT met its primary endpoint (8-K 2026-04-27) and the Federal Circuit affirmed the MINOCIN patents (10-Q, Item 2).
6. Valuation
All cases are 2027 based, with cash opex near the guided $145M to $155M. Bear (30%): add-on near the bottom of the range, or a large operator deprioritizes DefenCath. DefenCath $80M, Melinta $110M, adjusted EBITDA $20M at 6x plus net cash, about $4.25, with an oritavancin impairment plausible (10-Q, Critical Accounting Estimates). Base (45%): DefenCath at the $120M guidance midpoint, Melinta $125M, adjusted EBITDA $65M at 8x to 9x plus net cash, about $8.75. Bull (25%): top of the range plus the fifth operator ramping. DefenCath $150M, Melinta $135M, adjusted EBITDA $95M at 10x plus net cash and a free option on REZZAYO prophylaxis, about $13.00, capped by convert dilution at $13.47. Probability-weighted value is about $8.45 against $8.47. Reverse DCF: at a 10% to 11% discount rate with no growth, the $558M enterprise value implies $58M to $62M of sustainable after-tax free cash flow in perpetuity, almost exactly what management's own 2027 guidance plus the Melinta run rate produces. The market is pricing that number correctly.
7. Catalysts and timeline
CMS publication of the CY2027 ESRD add-on, effective January 1, 2027 and expected in the autumn rule cycle, is the whole thesis (10-K, Item 1). Q3 results in November show the trough and probably initial 2027 guidance. Label expansion: REZZAYO prophylaxis sNDA in Q3 2026, FDA action expected H1 2027 (8-K 2026-08-13); DefenCath in TPN completes Phase 3 in H1 2027 against a claimed $500M to $750M market. Inpatient NTAP expires November 14, 2026.
8. Risks and pre-registered kill criteria
- Q3 2026 DefenCath revenue below $15M, or a cut to the $325M to $345M FY26 range.
- The CY2027 add-on below three times $2.37, or a cut to the $100M to $140M FY2027 DefenCath guidance.
- Melinta revenue below $28M in a quarter, or an oritavancin impairment.
- Material weakness unremediated in the FY2026 10-K, or a third auditor change.
9. Verdict and one-paragraph summary
WATCH, conviction 3. CorMedix looks statistically absurd at 2.6x trailing EV/EBIT with $107M of net cash, but that multiple is an artifact: DefenCath's TDAPA reimbursement ended July 1, 2026 and dropped to a $2.37 add-on, and the company's own FY26 guidance implies a second half of $96M to $116M revenue and roughly zero adjusted EBITDA, after a first half that did $229M and $129M. The rebuild depends on a 2027 add-on that management estimates at three to five times the current rate but that CMS has not published, and even its reaffirmed 2027 DefenCath guidance of $100M to $140M sits below 2026 and well below 2025, so this is a lower plateau, not a round trip. With the top four customers at 82% of Q2 revenue, no insider buying in twelve months, an unremediated material weakness, and a probability-weighted value of about $8.45 against an $8.47 price, there is nothing to buy today. The rule and the Q3 print land within ninety days and settle it.
Research for discussion, not investment advice. Positions and sizing are the reader's decision.